ArticleArchivos de bronconeumologia2021
RIBRON: The spanish Online Bronchiectasis Registry. Characterization of the First 1912 Patients.
Article in Archivos de bronconeumologia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 2 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- Coexistence of COPD or asthma in patients with bronchiectasis: a systematic review and meta-analysis.BMC pulmonary medicine · 2026Pooled it
- Pooled it
- Nasal nitric oxide combined with clinical features for preliminary screening of primary ciliary dyskinesia in bronchiectasis.The European respiratory journal · 2026Article
- Initiation of inhaled antibiotic therapy in chronic airway diseases: the REPAIR registry.ERJ open research · 2026Article
- Review
- Selective activation of the unfolded protein response and proteolytic pathways in sarcopenic limb muscles of bronchiectasis patients.ERJ open research · 2026Article
- Risk factors and prediction model for chronic bacterial infection in stable bronchiectasis in Shanghai, China.Frontiers in medicine · 2026Article
- Allergic bronchopulmonary aspergillosis andJournal of thoracic disease · 2025Review
- Primary Humoral Immunodeficiencies and Bronchiectasis in Adults.Journal of clinical medicine · 2025Review
- What is the optimal dose of N-acetylcysteine in adult patients with bronchiectasis?-data from the RIBRON registry.Journal of thoracic disease · 2025Article
- Non-cystic fibrosis bronchiectasis in Taiwan.BMJ open respiratory research · 2025Observational
- Impact of body mass index on outcomes of non-cystic fibrosis bronchiectasis.BMJ open respiratory research · 2025Article
- The pharmacokinetics of brensocatib in participants with renal impairment following a single oral administration.British journal of clinical pharmacology · 2025Article
- The impact of COPD-bronchiectasis association on clinical outcomes: insights from East Asian cohorts validating the ROSE criteria.ERJ open research · 2025Article
- Post-tuberculous bronchiectasis in adults: The never-ending story.Journal of clinical tuberculosis and other mycobacterial diseases · 2025Article
- Primary Ciliary Dyskinesia in Adult Bronchiectasis: Data from the German Bronchiectasis Registry PROGNOSIS.Chest · 2024Article
- Therapeutic Management of Bronchiectasis in Children and Adolescents: A Concise Narrative Review.Journal of clinical medicine · 2024Review
- Infection and the microbiome in bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Pathophysiology and genomics of bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Idiopathic bronchiectasis. What are we talking about?Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 11 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe SEPAR Spanish Bronchiectasis Registry (RIBRON) began as a platform for the collection of longitudinal data on patients with this disease. The objective of this study is to describe its operation and to analyze the characteristics of bronchiectasis patients according to sex.
methodsA total of 1912 adult patients diagnosed with bronchiectasis in 43 centers were included between February 2015 and 2019. All patients had complete data consisting of at least 79 basic required variables, controlled by an external audit.
resultsMean age was 67.6 (15.2) years; 63.9% were women. The most common symptom was productive cough (78.3%) which was mucopurulent-purulent in 45.9% of cases. The most common etiology was post-infectious (40.4%), while 18.5% were idiopathic. Pseudomonas aeruginosa was the most frequently isolated microorganism (40.4%), of which 25.6% were associated with chronic infection. The annual number of mild-to-moderate/severe exacerbations was 1.62 (1.9)/0.59 (1.3). Half of the patients (50%) presented with airflow obstruction (17% severe). The most frequent radiological localization was lower lobes. The average FACED/E-FACED/BSI values were 2.06 (1.7)/2.67 (2.2)/7.8 (4.5), respectively. Overall, 66.7% of patients were taking inhaled corticosteroids, 19.2% macrolides, and 19.5% inhaled antibiotics. Women presented a less severe profile than men in clinical and functional terms, and a similar infectious, radiological and therapeutic profile.
conclusionsRIBRON represents an excellent map of the characteristics of bronchiectasis in our country. Two thirds of patients are women who presented lower disease severity as a specific characteristic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.